Substituted sulfonamides as selective .beta..sub.3 agonists for the treatment of diabetes and obesity

A compound having the formula I:

• ##STR68## where n is 0 to 5;
• m is 0 or 1;
• r is 0 to 3;
• A is Pyridinyl;
• R.sup.1 is (1) hydroxy, (2) oxo, (3) halogen, (4) cyano, (5) NR.sup.8 R.sup.8, (6) SR.sup.8, (7) trifluoromethyl, (8) C.sub.1 -C.sub.10 alkyl, (9) OR.sup.8, (10) SO.sub.2 R.sup.9, (11) OCOR.sup.9, (12) NR.sup.8 COR.sup.9, (13) COR.sup.9, (14) NR.sup.8 SO.sub.2 R.sup.9, (15) NR.sup.8 CO.sub.2 R.sup.8, or (16) C.sub.1 -C.sub.10 alkyl substituted by hydroxy, halogen, cyano, NR.sup.8 R.sup.8, SR.sup.8, trifluoromethyl, OR.sup.8, C.sub.3 -C.sub.8 cycloalkyl, phenyl, NR.sup.8 COR.sup.9, COR.sup.9, SO.sub.2 R.sup.9, OCOR.sup.9, NR.sup.8 SO.sub.2 R.sup.9 or NR.sup.8 CO.sub.2 R.sup.8 ;
• R.sup.2 and R.sup.3 are independently (1) hydrogen, (2) C.sub.1 -C.sub.10 alkyl or (3) C.sub.1 -C.sub.10 alkyl with 1 to 4 substituents selected from hydroxy, C.sub.1 -C.sub.10 alkoxy, and halogen;
• X is (1) --CH.sub.2 --, (2) --CH.sub.2 --CH.sub.2 --, (3) --CH=CH-- or (4) --CH.sub.2 O--;
• R.sup.4 and R.sup.5 are independently (1)hydrogen, (2) C.sub.1 -C.sub.10 alkyl, (3) halogen, (4) NHR.sup.8, (5) OR.sup.8, (6) SO.sub.2 R.sup.9 or (7) NHSO.sub.2 R.sup.9 ;
• R.sup.6 is (1) hydrogen or (2) C.sub.1 -C.sub.10 alkyl;
• R.sup.7 is Z-(R.sup.1a).sub.n ;
• R.sup.1a is (1) R.sup.1, (2) C.sub.3 -C.sub.8 cycloalkyl, (3) phenyl optionally substituted with up to 4 groups independently selected from R.sup.8, NR.sup.8 R.sup.8, OR.sup.8, SR.sup.8 and halogen, or (4) 5 or 6-membered heterocycle with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen, optionally substituted with up to four groups independently selected from oxo, R.sup.8, NR.sup.8 R.sup.8, OR.sup.8, SR.sup.8, and halogen;
• Z is (1) phenyl, (2) naphthyl, (3) a 5 or 6-membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen, (4) a benzene ring fused to a C.sub.3 -C.sub.8 cycloalkyl ring, (5) a benzene ring fused to a 5 or 6-membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen, (6) a 5 or 6-membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen fused to a 5 or 6-membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen, or (7) a 5 or 6-membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen fused to a C.sub.3 -C.sub.8 cycloalkyl ring;
• R.sup.8 is (1 ) hydrogen, (2) C.sub.1 -C.sub.10 alkyl, (3) C.sub.3 -C.sub.8 cycloalkyl, (4) Z optionally having 1 to 4 substituents selected from halogen, nitro, oxo, NR.sup.10 R.sup.10, C.sub.1 -C.sub.10 alkyl, C.sub.1 -C.sub.10 alkoxy, C.sub.1 -C.sub.10 alkylthio, and C.sub.1 -C.sub.10 alkyl having 1 to 4 substituents selected from hydroxy, halogen, CO.sub.2 H, CO.sub.2 --C.sub.1 --C.sub.10 alkyl,
• SO.sub.2 --C.sub.1 --C.sub.10 alkyl, C.sub.3 -C.sub.8 cycloalkyl, C.sub.1 -C.sub.10 alkoxy, and Z optionally substituted by from 1 to 3 of halogen, C.sub.1 -C.sub.10 alkyl or C.sub.1 -C.sub.10 alkoxy, or (5) C.sub.1 -C.sub.10 alkyl having 1 to 4 substituents selected from hydroxy, halogen, CO.sub.2 H, CO.sub.2 --C.sub.1 --C.sub.10 alkyl, SO.sub.2 --C.sub.1 --C.sub.10 alkyl, C.sub.3 -C.sub.8 cycloalkyl, C.sub.1 -C.sub.10 alkoxy, C.sub.1 -C.sub.10 alkyl, and Z optionally substituted by from 1 to 4 of halogen, C.sub.1 -C.sub.10 alkyl or C.sub.1 -C.sub.10 alkoxy;
• R.sup.9 is (1) R.sup.8 or (2) NR.sup.8 R.sup.8 ;
• R.sup.10 is (1) C.sub.1 -C.sub.10 alkyl, or (2) two R.sup.10 groups together with the N to which they are attached formed a 5 or 6-membered ring optionally substituted with C.sub.1 -C.sub.10 alkyl;
• or
• a pharmaceutically acceptable salt thereof.